Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
34 patients who received treatment; 28 (82%) have prior systemic antitumour therapy, with 19 (68%) pretreated patients having programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 1.
I · Intervention 중재 / 시술
at least first-line platinum-based chemotherapy or were unable to receive standard treatment in China
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
추출되지 않음
OpenAlex 토픽 ·
Endometrial and Cervical Cancer Treatments
HER2/EGFR in Cancer Research
Natural Compounds in Disease Treatment
[BACKGROUND] Efficacy of second-line treatments after first-line platinum-based chemotherapy in advanced cervical cancer is modest.
- 95% CI 85-100
APA
Xiaohua Wu, Danbo Wang, et al. (2026). Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study.. Communications medicine. https://doi.org/10.1038/s43856-026-01572-z
MLA
Xiaohua Wu, et al.. "Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study.." Communications medicine, 2026.
PMID
42014919 ↗
Abstract 한글 요약
[BACKGROUND] Efficacy of second-line treatments after first-line platinum-based chemotherapy in advanced cervical cancer is modest. This open-label, single-arm, multicentre, proof-of-concept phase 2 study evaluated fruquintinib plus sintilimab in advanced cervical cancer.
[METHODS] Patients recruited between July 2021 and June 2022 had received at least first-line platinum-based chemotherapy or were unable to receive standard treatment in China. Patients received fruquintinib 5 mg once daily orally (2 weeks on/1 week off) plus sintilimab 200 mg intravenously every 3 weeks. Efficacy and safety analyses included patients who had received at least one dose of study drug.
[RESULTS] Here we show the results of 34 patients who received treatment; 28 (82%) have prior systemic antitumour therapy, with 19 (68%) pretreated patients having programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 1. The objective response rate (ORR) is 32% (95% confidence interval [CI] 17-51), meeting the prespecified effective boundary, and the disease control rate (DCR) is 97% (95% CI 85-100). Median progression-free survival (PFS) and overall survival (OS) are 8.3 months (95% CI 5.5-19.4) and 23.5 months (95% CI 15.8-not estimable [NE]), respectively. The most common grade ≥ 3 treatment-related adverse event is palmar-plantar erythrodysaesthesia syndrome (21%). In pretreated patients with PD-L1 CPS ≥ 1, ORR is 37% (95% CI 16-62), median PFS is 19.4 months (95% CI 4.0-22.1), and OS rate at 18 months is 72% (95% CI 46-87).
[CONCLUSIONS] Fruquintinib plus sintilimab may indicate favourable and durable antitumour activity with a manageable safety profile in advanced cervical cancer, especially in pretreated patients with PD-L1 CPS ≥1, warranting further investigation.
[METHODS] Patients recruited between July 2021 and June 2022 had received at least first-line platinum-based chemotherapy or were unable to receive standard treatment in China. Patients received fruquintinib 5 mg once daily orally (2 weeks on/1 week off) plus sintilimab 200 mg intravenously every 3 weeks. Efficacy and safety analyses included patients who had received at least one dose of study drug.
[RESULTS] Here we show the results of 34 patients who received treatment; 28 (82%) have prior systemic antitumour therapy, with 19 (68%) pretreated patients having programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 1. The objective response rate (ORR) is 32% (95% confidence interval [CI] 17-51), meeting the prespecified effective boundary, and the disease control rate (DCR) is 97% (95% CI 85-100). Median progression-free survival (PFS) and overall survival (OS) are 8.3 months (95% CI 5.5-19.4) and 23.5 months (95% CI 15.8-not estimable [NE]), respectively. The most common grade ≥ 3 treatment-related adverse event is palmar-plantar erythrodysaesthesia syndrome (21%). In pretreated patients with PD-L1 CPS ≥ 1, ORR is 37% (95% CI 16-62), median PFS is 19.4 months (95% CI 4.0-22.1), and OS rate at 18 months is 72% (95% CI 46-87).
[CONCLUSIONS] Fruquintinib plus sintilimab may indicate favourable and durable antitumour activity with a manageable safety profile in advanced cervical cancer, especially in pretreated patients with PD-L1 CPS ≥1, warranting further investigation.
같은 제1저자의 인용 많은 논문 (5)
- Artificial Intelligence Models Integrating Preoperative Prostate MRI and Clinical Parameters for Predicting Extraprostatic Extension: A Systematic Review and Meta-Analysis.
- Loss of UFL1 confers enzalutamide resistance of prostate tumors by regulating METTL16-mediated m6A modification of EEF1A1 mRNA.
- Development and validation of a predictive and prognostic model of perineural invasion in colorectal cancer.
- Host-microbe interactions in NAD metabolism.
- Interpretable Machine Learning Model for Predicting Prolonged Postoperative Length of Stay in Lung Cancer Patients Undergoing Day Surgery: A Retrospective Cohort Study.